Skip to main content
. Author manuscript; available in PMC: 2024 Apr 2.
Published in final edited form as: Cancer Res. 2020 Nov 17;81(3):671–684. doi: 10.1158/0008-5472.CAN-20-1414

Figure 7: Enhanced survival of orthotopic 4T1 tumor bearing mice with FA-TLR7 treatment.

Figure 7:

(A) 4T1 Orthotopic tumors were established as described in Fig. 5 and treated with 10 nmol/mouse daily with FA-TLR7 by IV injection (5 days on 2 days off) for 5 weeks total. Mice were monitored for tumors that reached 2 cm in any direction or open ulcerated tumors. (B) Histology sections from each tumor were analyzed at the time of harvest for CD8+ infiltration by counting 10 fields of the tumor section at 20x magnification. Total counts were quantified from each FA-TLR7a treated tumor and each control tumor.